

## AMENDMENTS


In the Specification:

Please amend the specification as follows:

at p. 122

ABSTRACT

Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, the following structure and their use as fructose 1,6-bisphosphatase inhibitors is described.


Formula 1

wherein

- A is selected from the group consisting of  $\text{NR}_2^8$ ,  $\text{NHSO}_2\text{R}^3$ ,  $\text{OR}^5$ ,  $\text{SR}^5$ , halo, lower alkyl,  $\text{CON}(\text{R}^3)_2$ , guanidino, amidino, H, and perhaloalkyl;
- E is selected from the group consisting of H, halo, lower alkylthio, lower perhaloalkyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, CN, and  $\text{NR}_2^7$ ;
- X is selected from the group consisting of alk-NR, alkylene, alkenylene, alkynylene, arylene, heteroarylene, alk-NR-alk, alk-O-alk, alk-S-alk, alk-S-, alicyclicene, heterocyclicene, 1,1-dihaloalkylene, C(O)-alk, NR-C(O)-NR', alk-NR-C(O)-, alk-C(O)-NR-, Ar-alk, and alk-Ar, all optionally substituted, wherein each R and R' is independently selected from H and lower alkyl, and wherein each "alk" and "Ar" is an independently selected alkylene or arylene, respectively;

~~Y is selected from the group consisting of H, alkyl, alkenyl, alkynyl, aryl, alicyclic, heteroalicyclic, aralkyl, aryloxyalkyl, alkoxyalkyl, C(O)R<sup>3</sup>, S(O)<sub>2</sub>R<sup>3</sup>, C(O)OR<sup>3</sup>, CONHR<sup>3</sup>, NR<sup>2</sup>, and OR<sup>3</sup>, all except H are optionally substituted;~~

~~R<sup>4</sup> is independently selected from the group consisting of H, alkyl, aryl, heteroalicyclic where the cyclic moiety contains a carbonate or thiocarbonate, C(R<sup>2</sup>)<sub>2</sub>aryl, alkylaryl, C(R<sup>2</sup>)<sub>2</sub>OC(O)NR<sup>2</sup>, NR<sup>2</sup>C(O)R<sup>3</sup>, C(R<sup>2</sup>)<sub>2</sub>OC(O)R<sup>3</sup>, C(R<sup>2</sup>)<sub>2</sub>O-C(O)OR<sup>3</sup>, C(R<sup>2</sup>)<sub>2</sub>OC(O)SR<sup>3</sup>, alkylS-C(O)R<sup>3</sup>, alkylS-alkylhydroxy, and alkylS-S-alkylhydroxy, or together R<sup>4</sup> and R<sup>4</sup> are alkylS-S-alkyl to form a cyclic group, wherein each "alkyl" is an independently selected alkylene, or together R<sup>4</sup> and R<sup>4</sup> are~~



~~wherein~~

~~V and W are independently selected from the group consisting of hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, 1-alkenyl, 1-alkynyl, and R<sup>9</sup>; or~~

~~together V and Z are connected via a chain of 3-5 atoms, only one of which can be a heteroatom, to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxy-carboxy, or aryloxy-carboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus; or~~

~~together V and W are connected via a chain of 3 carbon atoms to form part of a cyclic group substituted with hydroxy, acyloxy, alkoxy-carboxy, alkylthiocarboxy, hydroxymethyl, or aryloxy-carboxy attached to a carbon atom that is three atoms from an oxygen attached to the phosphorus;~~

~~Z is selected from the group consisting of CH<sub>2</sub>OH, CH<sub>2</sub>OCOR<sup>3</sup>, CH<sub>2</sub>OC(O)SR<sup>3</sup>, CH<sub>2</sub>OCO<sub>2</sub>R<sup>3</sup>, SR<sup>3</sup>, S(O)R<sup>3</sup>, CH<sub>2</sub>N<sub>3</sub>, CH<sub>2</sub>NR<sup>2</sup>, CH<sub>2</sub>Ar, CH(Ar)OH, CH(CH=CR<sup>2</sup>)OH, CH(C≡CR<sup>2</sup>)OH, and R<sup>2</sup>-.~~

— with the provisos that:

- a) ~~V, Z, W are not all H; and~~
- b) ~~when Z is R<sup>2</sup>, then at least one of V and W is not H or R<sup>9</sup>;~~
- R<sup>2</sup> is selected from the group consisting of R<sup>3</sup> and H;
- R<sup>3</sup> is selected from the group consisting of alkyl, aryl, alicyclic, heteroalicyclic, and aralkyl;
- R<sup>4</sup> is independently selected from the group consisting of H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, and lower aryl;
- R<sup>5</sup> is selected from the group consisting of lower alkyl, lower aryl, lower aralkyl, lower alicyclic, and lower heteroalicyclic;
- R<sup>6</sup> is independently selected from the group consisting of H, and lower alkyl;
- R<sup>7</sup> is independently selected from the group consisting of H, lower alkyl, lower alicyclic, lower heteroalicyclic, lower aralkyl, lower aryl, and C(O)R<sup>10</sup>;
- R<sup>8</sup> is independently selected from the group consisting of H, lower alkyl, lower aralkyl, lower aryl, lower alicyclic, C(O)R<sup>10</sup>, or together said R<sup>8</sup> groups form a bidendate alkylene;
- R<sup>9</sup> is selected from the group consisting of alkyl, aralkyl, alicyclic, and heteroalicyclic;
- R<sup>10</sup> is selected from the group consisting of H, lower alkyl, NH<sub>2</sub>, lower aryl, and lower perhaloalkyl;
- R<sup>11</sup> is selected from the group consisting of alkyl, aryl, OH, NH<sub>2</sub> and OR<sup>3</sup>; and pharmaceutically acceptable prodrugs and salts thereof.